Endo Plans Valstar Relaunch In Second Half
This article was originally published in The Pink Sheet Daily
Bladder cancer drug, pulled from the market in 2002, became part of Endo’s portfolio when it acquired Indevus.
You may also be interested in...
Endo licenses axomadol for chronic pain and diabetic neuropathic pain from Grunenthal; sNDA for Valstar in bladder cancer also approved.
Re-submission of Nebido NDA in the wings, sales force will target general practitioners with urology, endocrinology drugs to general practitioners.
The company reported positive data from two Phase IIIb trials testing RelabotulinumtoxinA and said it hopes to refile a BLA for the aesthetic dermatology product soon.